
Adverum Biotechnologies ADVM
Quarterly report 2025-Q3
added 11-12-2025
Adverum Biotechnologies EV - Enterprise Value 2011-2026 | ADVM
Annual EV - Enterprise Value Adverum Biotechnologies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125 M | 31.4 M | 136 M | 262 M | 776 M | 648 M | 43.3 M | 294 M | -99.9 M | -54.5 M | 756 M | 739 K | 1.03 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 776 M | -99.9 M | 225 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | ||
|
BioNTech SE
BNTX
|
-4.91 B | $ 97.5 | -5.75 % | $ 27.2 B | ||
|
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M | ||
|
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | ||
|
Burford Capital Limited
BUR
|
3.22 B | $ 5.12 | 3.75 % | $ 820 M | ||
|
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M | ||
|
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
3.33 B | $ 21.94 | -2.27 % | $ 3.64 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
Cerus Corporation
CERS
|
632 M | $ 2.55 | 25.37 % | $ 486 M | ||
|
Athira Pharma
ATHA
|
-4.92 M | - | - | $ 269 M | ||
|
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B | ||
|
Atreca
BCEL
|
94.8 M | - | -11.76 % | $ 5.79 M | ||
|
Berkeley Lights
BLI
|
115 M | - | -7.31 % | $ 87 M | ||
|
Calithera Biosciences
CALA
|
916 M | - | -10.95 % | $ 876 K | ||
|
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | ||
|
CymaBay Therapeutics
CBAY
|
3.36 B | - | - | $ 3.45 B | ||
|
ChemoCentryx
CCXI
|
91.4 M | - | - | $ 3.74 B | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
Caladrius Biosciences
CLBS
|
-6.94 M | - | -16.75 % | $ 25.8 M | ||
|
Cardiff Oncology
CRDF
|
115 M | $ 1.72 | -0.87 % | $ 115 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
11.4 M | - | - | $ 231 M | ||
|
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
1.24 B | - | - | $ 2.18 B | ||
|
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | ||
|
Dynavax Technologies Corporation
DVAX
|
2.02 B | - | - | $ 2.02 B | ||
|
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | ||
|
Editas Medicine
EDIT
|
218 M | $ 2.91 | -3.17 % | $ 258 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 2.93 | -8.15 % | $ 4.82 M | ||
|
Eiger BioPharmaceuticals
EIGR
|
31 M | - | -9.21 % | $ 2.55 M | ||
|
Edesa Biotech
EDSA
|
6.91 M | $ 17.74 | -2.93 % | $ 56.7 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
18.7 M | - | -5.68 % | $ 8.28 M | ||
|
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | ||
|
Applied Therapeutics
APLT
|
563 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | ||
|
Evogene Ltd.
EVGN
|
-4.88 M | $ 0.79 | 1.67 % | $ 27.9 M | ||
|
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
38.2 M | - | 17.91 % | $ 11.1 M |